期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 64, 期 3, 页码 319-327出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.03.049
关键词
aspirin; bleeding; cancer; death; myocardial infarction; primary prevention
资金
- Bayer
- BMS/Pfizer
- Daiichi Sankyo
- Eli Lilly
- Alfa Wassermann
- Teofarma
- Bayer Healthcare
- Bristol-Myers Squibb
- AstraZeneca
- Eli Lilly/Daiichi Sankyo
- Sanofi-Aventis
- Boehringer Ingelheim
- Pfizer
Although the use of oral anticoagulants (vitamin K antagonists) has been abandoned in primary cardiovascular prevention due to lack of a favorable benefit-to-risk ratio, the indications for aspirin use in this setting continue to be a source of major debate, with major international guidelines providing conflicting recommendations. Here, we review the evidence in favor and against aspirin therapy in primary prevention based on the evidence accumulated so far, including recent data linking aspirin with cancer protection. While awaiting the results of several ongoing studies, we argue for a pragmatic approach to using low-dose aspirin in primary cardiovascular prevention and suggest its use in patients at high cardiovascular risk, defined as >= 2 major cardiovascular events (death, myocardial infarction, or stroke) projected per 100 person-years, who are not at increased risk of bleeding. (C) 2014 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据